Mahasti Saghatchian1, Céline Bihan2, Catherine Chenailler3, Chafika Mazouni4, Sarah Dauchy5, Suzette Delaloge2. 1. Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France. Electronic address: mahasti.saghatchian@gustaveroussy.fr. 2. Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France. 3. Institut Gustave Roussy, Department of Pharmacy, Villejuif, France. 4. Institut Gustave Roussy, Department of Surgery, Villejuif, France. 5. Institut Gustave Roussy, Department of Supportive Care and Psycho-oncology, Villejuif, France.
Abstract
INTRODUCTION: Complementary and alternative medicine (CAM) is increasingly popular among cancer patients but can interfere with conventional therapies; timely data are needed to adapt current patients' care. MATERIALS AND METHODS: This transversal, prospective study evaluated the use of CAM among patients receiving adjuvant chemotherapy or endocrine therapy for early stage breast cancer. We assessed the prevalence of use, the motivations and predictive factors for use, as well as patients' information needs over a three months period. RESULTS: 69/184 responders (37.5%) reported using at least one CAM. CAM use was associated with younger age (p = 0.03) and higher education level (p < 0.001). Pharmacological substances (e.g., homeopathy, phytotherapy) were the most commonly used (79.7%) before physical means (42%) and dietary methods (31.9%). A total of 65.8% of users felt that these treatments have demonstrated evidence of efficacy and 74.8% that they were not associated with side effects. The main goal for use was improvement of treatment-related symptoms (28.3%); secondary goal was increasing the general health status (20.5%). Patients reported high needs for information on CAMs. CAM use was associated with mild differences in secondary adverse events reported by patients. CONCLUSION: Breast cancer patients are common users of CAM concomitantly to their conventional cancer treatments and should be investigated regarding their current consumption of CAM. Furthermore, they need advice evidence-based data on these treatments and potential interactions with on-going treatments.
INTRODUCTION: Complementary and alternative medicine (CAM) is increasingly popular among cancerpatients but can interfere with conventional therapies; timely data are needed to adapt current patients' care. MATERIALS AND METHODS: This transversal, prospective study evaluated the use of CAM among patients receiving adjuvant chemotherapy or endocrine therapy for early stage breast cancer. We assessed the prevalence of use, the motivations and predictive factors for use, as well as patients' information needs over a three months period. RESULTS: 69/184 responders (37.5%) reported using at least one CAM. CAM use was associated with younger age (p = 0.03) and higher education level (p < 0.001). Pharmacological substances (e.g., homeopathy, phytotherapy) were the most commonly used (79.7%) before physical means (42%) and dietary methods (31.9%). A total of 65.8% of users felt that these treatments have demonstrated evidence of efficacy and 74.8% that they were not associated with side effects. The main goal for use was improvement of treatment-related symptoms (28.3%); secondary goal was increasing the general health status (20.5%). Patients reported high needs for information on CAMs. CAM use was associated with mild differences in secondary adverse events reported by patients. CONCLUSION:Breast cancerpatients are common users of CAM concomitantly to their conventional cancer treatments and should be investigated regarding their current consumption of CAM. Furthermore, they need advice evidence-based data on these treatments and potential interactions with on-going treatments.
Authors: Jasmina Makarević; Jochen Rutz; Eva Juengel; Silke Kaulfuss; Igor Tsaur; Karen Nelson; Jesco Pfitzenmaier; Axel Haferkamp; Roman A Blaheta Journal: PLoS One Date: 2014-10-15 Impact factor: 3.240
Authors: Bidisha Paul; Kendra J Royston; Yuanyuan Li; Matthew L Stoll; Christine F Skibola; Landon S Wilson; Stephen Barnes; Casey D Morrow; Trygve O Tollefsbol Journal: PLoS One Date: 2017-12-21 Impact factor: 3.240